12 completed. 12 Phase 2, 3 Phase 3.
By phase and status
Follow elbasvir: new trials by email Literature Review of elbasvir trials Research Report on elbasvir
Trials (filtered) newest first · largest first
All 12 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules - HCV Infection | Phase 2 | Completed | Merck Sharp & Dohme LLC | 57 | 2018-01-25 | 2023-05-31 |
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C | Phase 2 | Completed | University of Dundee | 129 | 2018-01-19 | 2021-11-18 |
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 15 | 2016-12-09 | 2025-07-15 |
Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)
Grazoprevir, Elbasvir, Ribavirin - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 101 | 2016-01-05 | 2019-08-13 |
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Grazoprevir, Uprifosbuvir, Elbasvir - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 413 | 2015-01-28 | 2019-07-30 |
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
Grazoprevir, Uprifosbuvir, Elbasvir - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 443 | 2015-01-22 | 2019-07-23 |
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Grazoprevir, Elbasvir, Placebo to Grazoprevir - Hepatitis C | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 399 | 2014-08-01 | 2018-09-24 |
Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)
Grazoprevir (GZR), Elbasvir (EBR), Ribavirin (RBV) - Hepatitis C Virus | Phase 2 | Completed | Merck Sharp & Dohme LLC | 79 | 2014-05-23 | 2018-09-24 |
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
Grazoprevir, Elbasvir, MK-5172A - Chronic Hepatitis C | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 40 | 2014-05-09 | 2019-06-26 |
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
Grazoprevir, Elbasvir, Placebo to Grazoprevir - Hepatitis C Virus | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 237 | 2014-03-17 | 2018-09-24 |
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
Grazoprevir, Elbasvir, Ribavirin - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 98 | 2013-10-01 | 2021-02-04 |
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Grazoprevir, Elbasvir, Placebo to Elbasvir - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 573 | 2013-02-07 | 2021-02-05 |
Conditions studied
Hepatitis C (11) · Carcinoma, Hepatocellular (1) · Hepatitis C, Chronic (1) · Substance-Related Disorders (1)
Sponsors
Merck Sharp & Dohme LLC (10) · M.D. Anderson Cancer Center (1) · University of Dundee (1)
Countries
United States (2) · Germany (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Top investigators
Ahmed O Kaseb, MD (1) · John Dillon, MD (1)
Results publications
PMID 28193518, PMID 28802814, PMID 28802816, PMID 26371152, PMID 26456905, PMID 27873094, PMID 28470815, PMID 28576451, PMID 29152828, PMID 29404492, PMID 29461687, PMID 29473975, PMID 30680407, PMID 30939489, PMID 31399460, PMID 35582875, PMID 36790337, PMID 37096802
NIH funding
2014 (3), 2015 (2), 2017 (1)